JNJ-78278343, JNJ-86974680 clinical trials

A study of Pasritamig (JNJ-78278343) in combination with JNJ-86974680 for treatment of prostate cancer

This study is testing two new drugs, Pasritamig and JNJ-86974680, together for men with advanced prostate cancer. Researchers want to find the safest dose and see if it helps fight the cancer. It's a very early-stage trial.